Verona Pharma starts asthma drug Phase II trial
The company has also treated first patient in the trial. The RPL554 compound is a new bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Almac has implemented biocatalytic technology for metabolite synthesis, isolation and structural identification. Metabolite synthesis is another tool within selectAZyme’s service providing access to both oxidative and glycosylated products.